| B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) (NCT04897321) | St. Jude Children's Research Hospital | 2022-07-06 |
| 18F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With Neuroblastoma (NCT05826158) | Rigshospitalet, Denmark | 2022-06-06 |
| Psychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families (NCT05245123) | Universitätsklinikum Hamburg-Eppendorf | 2022-02-21 |
| Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors (NCT05302921) | Children's National Research Institute | 2022-02-18 |
| Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma (NCT07516678) | Sun Yat-sen University | 2022-01-01 |
| 68Ga-DOTATATE Neuroblastoma Imaging Pilot (NCT04559217) | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | 2021-12-06 |
| Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. (NCT04909515) | Y-mAbs Therapeutics | 2021-12-02 |
| Phase 1 Study of BCD-245 in Subjects With Neuroblastoma (NCT05782959) | Biocad | 2021-11-29 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors (NCT04851119) | Children's Oncology Group | 2021-11-08 |
| Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors (NCT04337177) | Valent Technologies, LLC | 2021-10-25 |
| PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy (NCT04837547) | University of Florida | 2021-09-20 |
| 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor (NCT05069220) | Peking Union Medical College Hospital | 2021-09-01 |
| Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study. (NCT05027386) | Sun Yat-sen University | 2021-08-26 |
| A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma (NCT04936529) | Memorial Sloan Kettering Cancer Center | 2021-08-02 |
| Diagnostic Efficacy and Prognostic Value of 18F-FDG PET/CT (MR) in Pediatric Solid Blastoma (NCT06190574) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2021-07-30 |
| A Study of N9 Chemotherapy in Children With Neuroblastoma (NCT04947501) | Memorial Sloan Kettering Cancer Center | 2021-06-22 |
| A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer (NCT04730349) | Bristol-Myers Squibb | 2021-06-03 |
| 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma (NCT04903899) | Jakob Stenman | 2021-05-19 |
| Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor (NCT04864821) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2021-05-14 |
| Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib (NCT04753658) | Pfizer | 2021-03-19 |
| 18F-DOPA II - PET Imaging Optimization (NCT04706910) | University of Alberta | 2021-01-20 |
| Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Children (NCT05179850) | West China Hospital | 2021-01-01 |
| Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) (NCT04385277) | Children's Oncology Group | 2020-12-31 |
| Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma (NCT04301843) | Giselle Sholler | 2020-09-25 |
| Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") (NCT04474678) | Medical University of Vienna | 2020-09-07 |
| 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma (NCT04023331) | Clarity Pharmaceuticals Ltd | 2020-08-18 |
| Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma (NCT06851221) | Meyer Children's Hospital IRCCS | 2020-08-05 |
| B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (NCT04483778) | Seattle Children's Hospital | 2020-07-13 |
| A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma (NCT04106219) | Eli Lilly and Company | 2020-06-11 |
| 9-ING-41 in Pediatric Patients With Refractory Malignancies. (NCT04239092) | Actuate Therapeutics Inc. | 2020-06-05 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors (NCT04029688) | Hoffmann-La Roche | 2020-01-27 |
| Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging (NCT04017104) | British Columbia Cancer Agency | 2019-11-01 |
| A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects (NCT03561259) | Jubilant DraxImage Inc. | 2019-10-21 |
| A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta (NCT04253015) | RECORDATI GROUP | 2019-09-30 |
| An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors (NCT04040088) | Mayo Clinic | 2019-09-23 |
| EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (NCT03618381) | Seattle Children's Hospital | 2019-06-18 |
| Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors (NCT03709680) | Pfizer | 2019-05-24 |
| 18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma (NCT03541720) | St. Jude Children's Research Hospital | 2019-04-30 |
| Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas (NCT03478462) | Cellectar Biosciences, Inc. | 2019-04-30 |
| Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers (NCT03860207) | Y-mAbs Therapeutics | 2019-02-22 |
| Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma (NCT03721068) | UNC Lineberger Comprehensive Cancer Center | 2019-02-19 |
| Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells (NCT02573896) | New Approaches to Neuroblastoma Therapy Consortium | 2019-01-14 |
| 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases (NCT03275402) | Y-mAbs Therapeutics | 2018-12-11 |
| Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics] (NCT03686566) | University of Texas Southwestern Medical Center | 2018-11-16 |
| MIBG With Dinutuximab +/- Vorinostat (NCT03332667) | New Approaches to Neuroblastoma Therapy Consortium | 2018-09-12 |
| Nutritional Status in Neuroblastoma in Sao Paolo, Brazil (NCT03517280) | Columbia University | 2018-07-15 |
| DOTATOC PET/CT for Imaging NET Patients (NCT03583528) | British Columbia Cancer Agency | 2018-07-11 |
| Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma (NCT02914405) | University Hospital Southampton NHS Foundation Trust | 2018-05-24 |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (NCT03126916) | Children's Oncology Group | 2018-05-14 |
| Investigating the Microbiome and Volatile Organic Compound Profile of Children With Neuroblastoma (NCT03545542) | Medical University of Graz | 2018-05-07 |
| Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients (NCT03458728) | Bayer | 2018-04-30 |
| Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) (NCT03496402) | Institut Curie | 2018-04-20 |
| Oral Liquid 13-cis-retinoic Acid (13-CRA) (NCT03291080) | Nova Laboratories Limited | 2018-04-17 |
| Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow (NCT03363373) | Y-mAbs Therapeutics | 2018-04-03 |
| Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2 (NCT03209869) | University of Wisconsin, Madison | 2018-03-12 |
| Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors (NCT03373097) | Bambino Gesù Hospital and Research Institute | 2018-01-05 |
| A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies (NCT03236857) | AbbVie | 2017-11-08 |
| NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) (NCT03107988) | New Approaches to Neuroblastoma Therapy Consortium | 2017-09-05 |
| 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA (NCT02439788) | Baylor College of Medicine | 2017-08-01 |
| 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety (NCT03042416) | University of Alberta | 2017-06-29 |
| Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma (NCT03503864) | Yang Li | 2017-06-12 |
| Familial Investigations of Childhood Cancer Predisposition (NCT03050268) | St. Jude Children's Research Hospital | 2017-04-06 |
| Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies (NCT04308330) | New York Medical College | 2017-03-17 |
| A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma (NCT03033303) | Memorial Sloan Kettering Cancer Center | 2017-01-23 |
| Dosimetry Guided PRRT With 90Y-DOTATOC (NCT03013387) | Sue O'Dorisio | 2017-01-01 |
| International PPB/DICER1 Registry (NCT03382158) | Children's Hospitals and Clinics of Minnesota | 2016-12-06 |
| HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors (NCT02557854) | Theodore Laetsch | 2016-12-01 |
| Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors (NCT02982941) | MacroGenics | 2016-12-01 |
| Racotumomab in Patients With High-risk Neuroblastoma (NCT02998983) | Laboratorio Elea Phoenix S.A. | 2016-11-01 |
| Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma (NCT02909777) | Dana-Farber Cancer Institute | 2016-10-01 |
| Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients (NCT02924324) | Memorial Sloan Kettering Cancer Center | 2016-10-01 |
| A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors (NCT02536183) | AeRang Kim | 2016-10-01 |
| G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor (NCT02933333) | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 2016-09-27 |
| Neuroblastoma Precision Trial (NCT02868268) | New Approaches to Neuroblastoma Therapy Consortium | 2016-08-22 |
| Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) (NCT02624388) | University of Virginia | 2016-08-01 |
| Next Generation Personalized Neuroblastoma Therapy (NCT02780128) | Yael P Mosse | 2016-07-01 |
| High-Risk Neuroblastoma Chemotherapy Without G-CSF (NCT02786719) | Baylor College of Medicine | 2016-06-01 |
| Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma (NCT02605421) | Masonic Cancer Center, University of Minnesota | 2016-06-01 |
| A Combined Cell Therapy Approach to the Treatment of Neuroblastoma (NCT02745756) | H. Lee Moffitt Cancer Center and Research Institute | 2016-04-14 |
| Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients (NCT02693171) | United Therapeutics | 2016-03-15 |
| Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors (NCT02508038) | University of Wisconsin, Madison | 2016-02-12 |
| Neuroblastoma Maintenance Therapy Trial (NCT02679144) | Giselle Sholler | 2016-02-01 |
| Impact of Image-defined Risk Factors on the Outcome of Patients With Neuroblastoma: A Retrospective Study (NCT02558244) | Assiut University | 2016-01-01 |
| Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma (NCT02765243) | Zhujiang Hospital | 2016-01-01 |
| Trial of Tolcapone With Oxaliplatin for Neuroblastoma (NCT02630043) | Giselle Sholler | 2015-12-01 |
| NB2013-HR German (GPOH) / Dutch (DCOG) Trial (NCT02641782) | University of Cologne | 2015-11-01 |
| Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma (NCT02615106) | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 2015-11-01 |
| Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma (NCT02298348) | New Approaches to Neuroblastoma Therapy Consortium | 2015-10-08 |
| Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (NCT02559778) | Giselle Sholler | 2015-09-01 |
| Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors (NCT02441062) | Sue O'Dorisio | 2015-09-01 |
| T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies (NCT02457650) | Shenzhen Second People's Hospital | 2015-04-01 |
| Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma (NCT02743429) | University Medicine Greifswald | 2015-03-27 |
| Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission (NCT02395666) | Giselle Sholler | 2015-03-05 |
| Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors (NCT02390843) | Emory University | 2015-02-01 |
| ODSH + ICE Chemotherapy in Pediatric Solid Tumors (NCT02164097) | New York Medical College | 2015-01-01 |
| Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma (NCT02169609) | Fundació Sant Joan de Déu | 2014-11-26 |
| Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 (NCT02311621) | Seattle Children's Hospital | 2014-11-25 |
| PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study (NCT02307630) | Memorial Sloan Kettering Cancer Center | 2014-11-01 |
| A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas (NCT02130869) | St. Jude Children's Research Hospital | 2014-10-10 |
| Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma (NCT02245997) | Memorial Sloan Kettering Cancer Center | 2014-09-01 |